Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma

Lung Cancer

Volumn 73, Issue 3, 2011, Pages 361-365

  Uramoto, Hidetaka ^a   Shimokawa, Hidehiko ^a   Hanagiri, Takeshi ^a   Kuwano, Michihiko ^b   Ono, Mayumi ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Acquired resistance; Adenocarcinoma; EGFR; EGR 1; Lung cancer; PTEN

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GEFITINIB; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLAKOGLOBIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MESENCHYME CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CADHERINS; DRUG RESISTANCE, NEOPLASM; EARLY GROWTH RESPONSE PROTEIN 1; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBRONECTINS; GAMMA CATENIN; GENE EXPRESSION REGULATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79953687627     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.008     Document Type: Article

References (23)

1. Uramoto H., Sugio K., Oyama T., Ono K., Sugaya M., Yoshimatsu T., et al. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 2006, 51:71-77.
2. Uramoto H., Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. Br J Cancer 2007, 96:857-863.
3. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
4. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
5. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
6. Uramoto H., Sugio K., Oyama T., Sugaya M., Hanagiri T., Yasumoto K. A resistance to gefitinib. Int J Clin Oncol 2006, 11:487-491.
7. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
8. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
9. Onitsuka T., Uramoto H., Nose N., Takenoyama M., Hanagiri T., Sugio K., et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010, 68:198-203.
10. Uramoto H., Iwata T., Onitsuka T., Shimokawa H., Hanagiri T., Oyama T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010, 30:2513-2517.
11. Yamamoto C., Basaki Y., Kawahara A., Nakashima K., Kage M., Uramoto H., et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring EGFR activating mutations. Cancer Res 2010, 70:8715-8725.
12. Sobin L.H., Wittekind C. TNM classification of malignant tumors 2002, Wiley, New York. 6th ed.
13. Onitsuka T., Uramoto H., Ono K., Takenoyama M., Hanagiri T., Oyama T., et al. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET and hepatocyte growth factor status. J Thorac Oncol 2010, 5:591-596.
14. Yamashita T., Uramoto H., Onitsuka T., Ono K., Baba T., So T., et al. Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 2010, 70:320-328.
15. Cao X.M., Guy G.R., Sukhatme V.P., Tan Y.H. Regulation of the Egr-1 gene by tumor necrosis factor and interferons in primary human fibroblasts. J Biol Chem 1992, 267:1345-1349.
16. Loupakis F., Pollina L., Stasi I., Ruzzo A., Scartozzi M., Santini D., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:2622-2629.
17. Di Loreto C., Tell G., Pestrin M., Pandolfi M., Damante G., Puglisi F. PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett 2005, 224:105-109.
18. Uramoto H., Uchiumi T., Izumi H., Kohno K., Oyama T., Sugio K., et al. A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR. Anticancer Res 2007, 27:2297-2303.
19. Li Y., Guessous F., DiPierro C., Zhang Y., Mudrick T., Fuller L., et al. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther 2009, 8:376-385.
20. Wu X., Senechal K., Neshat M.S., Whang Y.E., Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998, 95:15587-15591.
21. Yamasaki F., Johansen M.J., Zhang D., Krishnamurthy S., Felix E., Bartholomeusz C., et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007, 67:5779-5788.
22. Sos M.L., Koker M., Weir B.A., Heynck S., Rabinovsky R., Zander T., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009, 69:3256-3261.
23. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations. Cancer Res 2008, 68:9479-9487.